CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 41 enrolled
Drug / intervention
tanespimycindrug
Likely dose
tanespimycin (17AAG) given intravenously (specific dose not stated)AI-extracted
Key inclusion· 7
  • ✓Medullary thyroid carcinoma OR differentiated thyroid carcinoma with iodine I-131 resistance
  • ✓Inoperable locoregionally advanced or metastatic disease
  • ✓Measurable disease: ≥1 lesion ≥2.0 cm by conventional imaging OR ≥1.0 cm by spiral CT
  • ✓No active CNS metastases
Key exclusion· 7
  • ✕Congenital long QT syndrome, left bundle branch block, or history of serious ventricular arrhythmias
  • ✕NYHA Class III or IV congestive heart failure, poorly controlled or recent angina
  • ✕History of uncontrolled dysrhythmias or requiring antiarrhythmic drugs
  • ✕Other active malignancy within past 5 years (except skin cancers)

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00118248
NCT00118248Phase 2Completed
CompareCT.gov

A Phase II Trial of 17-Allylaminogeldanamycin (17AAG) in Advanced Medullary and Differentiated Thyroid Carcinoma

National Cancer Institute (NCI)·interventional·Posted Jul 11, 2005·Updated Feb 15, 2017

In Brief

A Phase 2 clinical trial evaluating tanespimycin for Recurrent Thyroid Cancer and 3 related conditions. Completed, enrolled 41 participants across 1 site.

Detailed Summary

This phase II trial is studying how well tanespimycin works in treating patients with inoperable locoregionally advanced or metastatic thyroid cancer. Drugs used in chemotherapy, such as tanespimycin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRecurrent Thyroid Cancer, Stage IV Follicular Thyroid Cancer, Stage IV Papillary Thyroid Cancer, Thyroid Gland Medullary Carcinoma
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 11, 2005
Enrollment StartDec 1, 2004
Primary CompletionAug 1, 2009
Study CompletionApr 1, 2012
TodayJul 2, 2026
Enrollment to primary: 4.7 yearsPosted 21.0 years ago

Interventions

tanespimycindrug

Given IV